William C Yao, Randall Ow, Michael J Sillers, Nathan E Nachlas, Curtis D Johnson, Dale Ehmer, Jordan Pritikin, Henry P Barham
{"title":"Three-Year Outcomes After Temperature-Controlled Radiofrequency Treatment of Nasal Airway Obstruction.","authors":"William C Yao, Randall Ow, Michael J Sillers, Nathan E Nachlas, Curtis D Johnson, Dale Ehmer, Jordan Pritikin, Henry P Barham","doi":"10.1002/oto2.70111","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the long-term safety and effectiveness of temperature-controlled radiofrequency (TCRF) treatment of nasal valve collapse (NVC) in patients with nasal airway obstruction (NAO).</p><p><strong>Study design: </strong>This is an extended follow-up from a prospective, multicenter, single-arm study. The initial study included participants from 12 sites across the United States who were followed for 24 months and additionally agreed to participate in the extended 36-month follow-up.</p><p><strong>Setting: </strong>Procedure was performed in-office with an in-person follow-up at 3 months and subsequent follow-up assessment remotely.</p><p><strong>Methods: </strong>Participants received TCRF treatment of only the nasal valve and participated in the extended 36-month follow-up. The effect of TCRF treatment was determined by analyzing changes in nasal obstruction symptom evaluation (NOSE) score at each follow-up compared to the baseline.</p><p><strong>Results: </strong>Of the 122 participants in the primary study, 66 participated in the extended 36-month follow-up. Compared to baseline, there was a 52.6% decrease in the NOSE score at 36 months (mean change -45.3 [95% CI -52.3 to -38.3]; <i>P</i> < .001), and 83.3% of the participants met the criteria for treatment response at 36 months, as defined by the study endpoint. Post hoc sensitivity analysis of the treatment response for all participants from the time of enrollment was 73.9%. No device or procedure-related adverse events or serious adverse events were reported in the interval between 24 and 36 months.</p><p><strong>Conclusion: </strong>TCRF treatment of only the nasal valve resulted in significant and durable improvement in NAO symptoms through 36 months in participants with NAO due to NVC.</p>","PeriodicalId":19697,"journal":{"name":"OTO Open","volume":"9 2","pages":"e70111"},"PeriodicalIF":1.8000,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973577/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OTO Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/oto2.70111","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To evaluate the long-term safety and effectiveness of temperature-controlled radiofrequency (TCRF) treatment of nasal valve collapse (NVC) in patients with nasal airway obstruction (NAO).
Study design: This is an extended follow-up from a prospective, multicenter, single-arm study. The initial study included participants from 12 sites across the United States who were followed for 24 months and additionally agreed to participate in the extended 36-month follow-up.
Setting: Procedure was performed in-office with an in-person follow-up at 3 months and subsequent follow-up assessment remotely.
Methods: Participants received TCRF treatment of only the nasal valve and participated in the extended 36-month follow-up. The effect of TCRF treatment was determined by analyzing changes in nasal obstruction symptom evaluation (NOSE) score at each follow-up compared to the baseline.
Results: Of the 122 participants in the primary study, 66 participated in the extended 36-month follow-up. Compared to baseline, there was a 52.6% decrease in the NOSE score at 36 months (mean change -45.3 [95% CI -52.3 to -38.3]; P < .001), and 83.3% of the participants met the criteria for treatment response at 36 months, as defined by the study endpoint. Post hoc sensitivity analysis of the treatment response for all participants from the time of enrollment was 73.9%. No device or procedure-related adverse events or serious adverse events were reported in the interval between 24 and 36 months.
Conclusion: TCRF treatment of only the nasal valve resulted in significant and durable improvement in NAO symptoms through 36 months in participants with NAO due to NVC.
目的:评价温控射频(TCRF)治疗鼻气道梗阻(NAO)患者鼻瓣膜塌陷(NVC)的长期安全性和有效性。研究设计:这是一项前瞻性、多中心、单臂研究的扩展随访。最初的研究包括来自美国12个地点的参与者,他们被跟踪了24个月,并同意参加延长的36个月的随访。设置:手术在办公室进行,3个月时进行现场随访,随后进行远程随访评估。方法:参与者接受仅鼻瓣膜TCRF治疗,并参加延长36个月的随访。通过分析每次随访时鼻塞症状评估(NOSE)评分与基线相比的变化来确定TCRF治疗的效果。结果:在最初研究的122名参与者中,66人参加了延长的36个月的随访。与基线相比,36个月时NOSE评分下降52.6%(平均变化-45.3 [95% CI -52.3至-38.3];结论:在NVC引起的NAO患者中,TCRF仅对鼻阀进行治疗,在36个月的时间里,NAO症状得到了显著而持久的改善。